[Federal Register Volume 79, Number 28 (Tuesday, February 11, 2014)]
[Notices]
[Page 8192]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2014-02858]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention


Clinical Laboratory Improvement Advisory Committee

    In accordance with section 10(a)(2) of the Federal Advisory 
Committee Act (Pub L. 92-463), the Centers for Disease Control and 
Prevention (CDC) announces the following meeting of the aforementioned 
committee:

    Times and Dates:

8:30 a.m.-4:30 p.m., March 5, 2014
8:30 a.m.-12:00 p.m., March 6, 2014

    Place: CDC, 1600 Clifton Road NE., Tom Harkin Global 
Communications Center, Building 19, Auditorium B, Atlanta, Georgia 
30333. This meeting will also be Webcast, please see information 
below.
    Status: Open to the public, limited only by the space available. 
The meeting room accommodates approximately 100 people.
    Purpose: This Committee is charged with providing scientific and 
technical advice and guidance to the Secretary of Health and Human 
Services (HHS); the Assistant Secretary for Health; the Director, 
Centers for Disease Control and Prevention; the Commissioner, Food 
and Drug Administration (FDA); and the Administrator, Centers for 
Medicare and Medicaid Services (CMS). The advice and guidance 
pertain to general issues related to improvement in clinical 
laboratory quality and laboratory medicine practice and specific 
questions related to possible revision of the Clinical Laboratory 
Improvement Amendment (CLIA) standards. Examples include providing 
guidance on studies designed to improve safety, effectiveness, 
efficiency, timeliness, equity, and patient-centeredness of 
laboratory services; revisions to the standards under which clinical 
laboratories are regulated; the impact of proposed revisions to the 
standards on medical and laboratory practice; and the modification 
of the standards and provision of non-regulatory guidelines to 
accommodate technological advances, such as new test methods and the 
electronic transmission of laboratory information.
    Matters To Be Discussed: The agenda will include agency updates 
from CDC, CMS, and FDA. Presentations and discussions will include 
the CMS implementation of Individualized Quality Control Plan (IQCP) 
as a new CLIA quality control option based on risk management for 
laboratories performing nonwaived testing; CDC's strategic priority 
for strengthening public health and health care collaborations; and 
quality improvement tools for managing laboratory testing in 
ambulatory settings.
    Agenda items are subject to change as priorities dictate.
    Webcast: The meeting will also be Webcast. Persons interested in 
viewing the Webcast can access information at: http://wwwn.cdc.gov/cliac/default.aspx.
    Online Registration Required: All people attending the CLIAC 
meeting in-person are required to register for the meeting online at 
least 5 business days in advance for U.S. citizens and at least 10 
business days in advance for international registrants. Register at 
http://wwwn.cdc.gov/cliac/default.aspx by scrolling down and 
clicking the appropriate link under ``Meeting Registration'' (either 
U.S. Citizen Registration or Non-U.S. Citizen Registration) and 
completing all forms according to the instructions given. Please 
complete all the required fields before submitting your registration 
and submit no later than February 26, 2014 for U.S. registrants and 
February 19, 2014 for international registrants.
    Providing Oral or Written Comments: It is the policy of CLIAC to 
accept written public comments and provide a brief period for oral 
public comments whenever possible. Oral Comments: In general, each 
individual or group requesting to make oral comments will be limited 
to a total time of five minutes (unless otherwise indicated). 
Speakers must also submit their comments in writing for inclusion in 
the meeting's Summary Report. To assure adequate time is scheduled 
for public comments, speakers should notify the contact person below 
at least one week prior to the meeting date. Written Comments: For 
individuals or groups unable to attend the meeting, CLIAC accepts 
written comments until the date of the meeting (unless otherwise 
stated). However, it is requested that comments be submitted at 
least one week prior to the meeting date so that the comments may be 
made available to the Committee for their consideration and public 
distribution. Written comments, one hard copy with original 
signature, should be provided to the contact person below, and will 
be included in the meeting's Summary Report.
    Availability of Meeting Materials: To support the green 
initiatives of the federal government, the CLIAC meeting materials 
will be made available to the Committee and the public in electronic 
format (PDF) on the internet instead of by printed copy. Check the 
CLIAC Web site on the day of the meeting for materials. Note: If 
using a mobile device to access the materials, please verify that 
the device's browser is able to download the files from the CDC's 
Web site before the meeting. http://wwwn.cdc.gov/cliac/cliac_meeting_all_documents.aspx Alternatively, the files can be 
downloaded to a computer and then emailed to the portable device. An 
internet connection, power source and limited hard copies may be 
available at the meeting location, but cannot be guaranteed.
    Contact Person for Additional Information: Nancy Anderson, 
Chief, Laboratory Practice Standards Branch, Division of Laboratory 
Programs, Standards, and Services, Center for Surveillance, 
Epidemiology and Laboratory Services, Office of Public Health 
Scientific Services, Centers for Disease Control and Prevention, 
1600 Clifton Road NE., Mailstop F-11, Atlanta, Georgia 30329-4018; 
telephone (404) 498-2741; or via email at [email protected].
    The Director, Management Analysis and Services Office, has been 
delegated the authority to sign Federal Register Notices pertaining 
to announcements of meetings and other committee management 
activities, for CDC and the Agency for Toxic Substances and Disease 
Registry.

Elaine L. Baker,
Director, Management Analysis and Services Office, Centers for Disease 
Control and Prevention.
[FR Doc. 2014-02858 Filed 2-10-14; 8:45 am]
BILLING CODE 4163-18-P